Tetteh, EK; Morris, S; (2014) Evaluating the administration costs of biologic drugs: development of a cost algorithm. Health Econ Rev , 4 (1) 26-. 10.1186/s13561-014-0026-2.

Preview	Text (Article) s13561-014-0026-2.pdf Download (759kB) | Preview
Preview	Text (Appendix A: Dosing regimens modelled.) s13561-014-0026-2-s1.pdf Download (52kB) | Preview
Preview	Text (Appendix B: Summary of cost inputs.) s13561-014-0026-2-s2.pdf Download (64kB) | Preview

Abstract

Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to determine which medical technologies offer value-for-money. The manner in which these assessments are conducted suggests that, holding all else equal, the economic value of biologic drugs may be determined by how much is spent on administering these drugs or trade-offs between drug acquisition and administration costs. Yet, on the supply-side, it seems very little attention is given to how manufacturing and formulation choices affect healthcare delivery costs. This paper evaluates variations in the administration costs of biologic drugs, taking care to ensure consistent inclusion of all relevant cost resources. From this, it develops a regression-based algorithm with which manufacturers could possibly predict, during process development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their products.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item